Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

NCT06228053 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: SX-682
DRUG: Enzalutamide

Sponsor

Syntrix Biosystems, Inc.

Collaborators

[object Object]